Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Breast 2Tumor-Agnostic 1Other solid neoplasm 1Other 1Genitourinary 1CNS 1

Conditions

Chemotherapy-Induced Peripheral Neuropathy 1

Interventions

pembrolizumab 77Injections 67Carboplatin 38Nivolumab 31Pemetrexed 29Cisplatin 29Cyclophosphamide 25Specimen Handling 24Interviews as Topic 24tislelizumab 20atezolizumab 20Bevacizumab 20Paclitaxel 19fludarabine 16Standard of Care 16Practice Guidelines as Topic 16Docetaxel 16Ipilimumab 15toripalimab 14Educational Status 14Cetuximab 14Fluorouracil 13Oxaliplatin 12Etoposide 12olaparib 11durvalumab 11Methods 11Gemcitabine 11Early Intervention, Educational 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cannabidiol × Other solid neoplasm × 1 year × Clear all
NCT05388058 2026-01-16

Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

Mayo Clinic

Phase 2 Completed
40 enrolled 15 charts
OtherOther solid neoplasm

Chemotherapy-Induced Peripheral Neuropathy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡